Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.47 |
| ▸ | CHUK | O15111 | 4/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688528 | 0.87 | IKBKB (0.50) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4685170 | 0.86 | IKBKB (0.62) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4688542 | 0.85 | IKBKB (0.50) | IKBKBCHUKUSP30HPGDSAURKA | |
| SCHEMBL6644118 | 0.80 | KDM4E (0.46) | — | |
| SCHEMBL4685993 | 0.79 | IKBKB (0.66) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL14181451 | 0.79 | KDM4E (0.63) | HPGDSHSD11B1 | |
| SCHEMBL14030814 | 0.78 | IKBKB (0.47) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL27224129 | 0.74 | HPGDS (0.48) | USP30HPGDS | |
| SCHEMBL5255106 | 0.74 | KDM4E (0.56) | USP30HPGDSHSD11B1 | |
| SCHEMBL30834269 | 0.74 | KDM4E (0.56) | USP30HPGDSHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| CN-1933830-A | Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885USP30 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.